Dimerix Limited

DXB

AU000000DXB7

Biotechnology & Medical Research

Delayed Australian S.E. Other stock markets 10:27:37 2024-05-20 pm EDT			5-day change	1st Jan Change
0.345 ^AUD	-2.82%		+1.47%	+68.29%

May. 01	Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	MT
Apr. 22	Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	MT

Dimerix Limited Appoints Kathy Harrison as Chief Executive Officer

November 06, 2016 at 04:26 pm EST

Dimerix Limited announced the appointment of Kathy Harrison, current General Manager of Dimerix Biosciences Pty Ltd, to the role of Chief Executive Officer of the company.

Latest news about Dimerix Limited

Dimerix Secures Pediatric Plan Approval in the UK for Kidney Disease Medication	Apr. 30	MT
Dimerix Posts AU$35.2 Million Cash, AU$3.3 Million Operating Cash Outflows for March Quarter	Apr. 22	MT
Euroz Hartleys Starts Dimerix at Speculative Buy With AU$0.80 Price Target	Apr. 19	MT
Dimerix Raises AU$20 Million for Kidney Disease Study	Mar. 12	MT
Dimerix Expanding Kidney Drug Study After DMX-200 Performs Better than Placebo	Mar. 10	MT
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 25	CI
Dimerix Limited Announces Appointment of Mark Diamond as Director	Nov. 30	CI
Dimerix Secures Investigational New Drug Approval for Kidney Disease Medication in China; Shares Rally 11%	Nov. 27	MT
Dimerix Appoints Nonexecutive Chair	Nov. 19	MT
Dimerix Receives AU$10.7 Million Upfront Payment for Commercialization Rights	Nov. 07	MT
Dimerix Appoints Medical Chief	23-10-22	MT
Dimerix Limited Announces Appointment of Dr David Fuller as Chief Medical Officer	23-10-22	CI
Softer US Employment Data End Australian Shares' Three-Day Losing Streak	23-10-05	MT
Dimerix Surges 154% After Securing License Deal for Kidney Disease Drug	23-10-05	MT
Dimerix Secures Conditional US FDA Clearance for Kidney Medication Brand Name	23-09-25	MT
Dimerix Secures Regulatory Nod to Conduct Kidney Disease Drug Trial in Malaysia	23-09-22	MT
Dimerix Secures AU$9 Million R&D Tax Rebate; Shares Rise 3%	23-09-12	MT
Dimerix Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-29	CI
Dimerix Secures Approval for Pediatric Kidney Disease Plan in Europe	23-07-05	MT
Dimerix Secures Study Design Approval in China for Phase Three Kidney Disease Trial; Shares Rise 6%	23-07-02	MT
Dimerix Raising AU$12 Million to Continue Clinical Program; Shares Down 7%	23-05-03	MT
Dimerix Limited Appoints Clinton Snow New Non-Executive Director to the Board, Effective 01 May 2023	23-04-30	CI
Dimerix Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI
Dimerix Secures AU$2.8 Million in Prepayment of R&D Tax Rebate; Shares Rise 8%	23-02-16	MT
Dimerix Secures Safety Approval for Phase 3 Kidney Drug Trial	23-02-09	MT

Dimerix Limited is an Australia-based clinical-stage biopharmaceutical company. The Company is focused on developing lives of patients with inflammatory diseases, including both kidney and respiratory diseases. It develops and commercializes patient preferred pharmaceutical products for global markets using its receptor technology to identify and develop drugs in areas with an unmet need. The Company is focused on developing its Phase III product candidate DMX-200 (QYTOVRA), for Focal Segmental Glomerulosclerosis (FSGS) kidney disease and is also developing DMX-700 for Chronic Obstructive Pulmonary Disease (COPD). Its Receptor Heteromer Investigation Technology (Receptor-HIT) is a scalable and globally applicable technology platform enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. Its products target multiple global territories, with the initial focus predominantly on the United States and European markets.

Sector

Biotechnology & Medical Research

Calendar

2024-08-26 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
DIMERIX LIMITED	+68.29%	138M
MODERNA, INC.	+41.79%	50.93B
IQVIA HOLDINGS INC.	-0.56%	42.12B
LONZA GROUP AG	+49.62%	42.05B
CELLTRION, INC.	-7.20%	29.18B
ICON PUBLIC LIMITED COMPANY	+12.59%	26.02B
ALNYLAM PHARMACEUTICALS, INC.	-21.51%	18.9B
BIO-TECHNE CORPORATION	+6.92%	13.21B
UNITED THERAPEUTICS CORPORATION	+24.91%	12.17B
MEDPACE HOLDINGS, INC.	+29.60%	12.16B

Other Biotechnology & Medical Research

Dimerix Limited

Equities

DXB

AU000000DXB7

Biotechnology & Medical Research

Dimerix Limited Appoints Kathy Harrison as Chief Executive Officer

Latest news about Dimerix Limited

Chart Dimerix Limited

Company Profile

Income Statement Evolution

Sector Other Biotechnology & Medical Research